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Human genomic variation: from sequence to 
function
The recent development of high-throughput sequencing 
(HTS) and its application for sequencing the exomes or 
genomes of thousands of people (including participants 
of the 1000 Genomes Project) has provided experimental 
evidence of the extensive variability of the human genome 
(both  in  single  nucleotide  polymorphisms  (SNPs)  and 
copy  number  variations  (CNVs)).  Within  the  coding 
fraction of the genome (the exome), each individual is 
estimated  to  have  approximately  8,500  to  10,500  non-
synonymous variants, 350 to 400 of which are predicted 
to  cause  loss-of-function  alleles  affecting  250  to  300 
genes  [1].  HTS  data  have  also  provided  experimental 
evidence that the mutation rate of the human genome is 
10-8  per  nucleotide  per  generation,  resulting  in  two  to 
seven new variants in each individual exome [2].
The most difficult challenge for HTS projects aiming to 
discover pathogenic variants is the correct identification 
of  the  disease-causing  mutations  among  thousands  of 
additional variants that could be either contributing to 
unrecognized phenotypes or neutral [3]. At present, most 
HTS projects focus on the known functional elements of 
the genome. Protein-coding genes are at the heart of this 
analysis,  along  with  non-coding  transcripts  and  highly 
conserved non-coding sequences. The rules of heredity, 
gene expression data, evolutionary principles and protein 
structure-function relationships provide the current set 
of  criteria  for  deciding  between  potential  contributing 
and non-contributing variants relative to the phenotype 
in  question.  The  phenotype  is  also  an  important  con-
sidera  tion because identified variants may contribute to 
other phenotypes but not the one in question. Further-
more,  the  correlation  between  genome  variation  and 
phenotypic variation is relatively simple for monogenic/
oligogenic phenotypes and highly penetrant variants, but 
is complicated for polygenic phenotypes and for medium 
or low-penetrance variants.
More  precise  examples  of  these  criteria  are:  the 
presence of the variants and their allelic composition in 
affected  and  non-affected  individuals  according  to  the 
mode of inheritance imposed or hypothesized; the map-
ping position of the variants following linkage or asso-
ciation studies in families and populations; the predicted 
functional  consequence  of  the  variant  (missense, 
nonsense,  frameshift  or  splice-site);  the  evolutionary 
conservation  of  the  affected  codon;  the  expected 
disruption of the protein’s structure; the frequency of the 
variant  in  the  population  without  the  phenotype  in 
question; the potential disruption of a protein network; 
and  the  predicted  ‘recessive’  or  ‘dominant’  nature  of 
variants  in  a  gene  of  interest.  There  are  computer 
prediction  programs  using  some  of  these  criteria  for 
predicting  the  likely  pathogenicity  of  non-synonymous 
variants [4].
Establishing the function of human genomic 
variants
However, the ‘prior probability’ for the pathogenicity of 
the  majority  of  non-synonymous  variants  is  not  satis-
factory,  the  gray  zone  of  uncertainty  is  extensive,  and 
most  investigators  ultimately  require  experimental  evi-
dence  for  the  functionality  of  each  variant.  A  recently 
Abstract
DNA sequencing has become cheap, rapid and 
accurate, allowing us to access thousands of 
genomes and reveal the extensive variation among 
individuals. The major problem that arises from this 
is distinguishing between neutral and pathogenic 
variants. A recent study by Davis et al., in which a 
functional screen of all the non-synonymous variants 
of a newly discovered gene was performed, highlights 
the value and necessity of characterizing the functional 
consequences of each genomic variant discovered. 
This is the main challenge for the advancement of 
genomic medicine in the years to come.
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example of such a functional screening study. The authors 
studied the TTC21B gene in 753 patients with ciliopathies 
and 398 controls in order to examine the spectrum and 
disease  contribution  of  variants.  The  TTC21B  gene 
encodes  the  IFT139  protein,  which  is  involved  in 
retrograde intraflagellar transport in cilia and negatively 
modulates Sonic Hedgehog signal transduction [6]. Forty 
non-synonymous variants of TTC21B were identified in 
patients,  and  all  of  these  were  studied  in  a  functional 
assay using zebrafish embryos to establish pathogenicity. 
Briefly,  the  embryonic  phenotype  associated  with 
reduced levels of the zebrafish TTC21B ortholog can be 
rescued using human TTC21B mRNA. Different mRNAs 
carrying  HTS-identified  non-synonymous  variants  of 
this gene either failed to rescue or partially or completely 
rescued the phenotype; these represent functional null, 
hypomorphic and benign alleles, respectively. The func-
tional studies provided evidence for TTC21B causative 
variants  in  ciliopathies  such  as  Jeune  asphyxiating 
thoracic dystrophy (JATD) and nephronophthisis (NPHP); 
furthermore, other TTC21B variants function as modifier 
alleles in additional ciliopathies. The functional evidence 
for each allelic variant is pivotal in the understanding of 
the observed phenotype. A caveat, however, is that we 
cannot  always  predict  the  effect  of  a  variant  on  the 
human  phenotype  from  the  experiments  in  model 
organisms. This is even more relevant in cases such as 
those studied by Davis et al. [5], in which a dysfunctional 
protein may result in different disorders.
For proteins for which there are functional assays, one 
could predict that databases will be developed with the 
functional  results  for  all  variants  detected  for  specific 
proteins.  Functional  validation  of  non-synonymous 
variants  could  be  performed  using  several  laboratory 
models,  using  either  whole  organisms  (such  as  yeast, 
Drosophila,  fish  or  mice),  or  cells  (such  as  cell-based 
models derived from humans or other organisms and in-
vitro-differentiated  cells).  The  advantage  of  such 
functional  assays  is  that  they  provide  not  only  the 
functional  proof  of  the  pathogenicity  of  a  variant,  but 
also  novel  insights  into  protein  function  and  perhaps 
even the mechanism of disease. Unfortunately, there are 
no  TTC21B-like  functional  assays  for  the  majority  of 
proteins, and most of the methods to test functionality 
are  not  amenable  to  large-scale  screening  approaches. 
Thus,  considerable  effort  should  be  made  to  develop 
large-scale  screening  assays  for  all  possible  non-
synonymous variants for all human proteins.
The challenges ahead
This is only the tip of the iceberg for the characterization 
of pathogenic variants. Assays need to be developed for 
the  assessment  of  variants  in  all  functional  genomic 
elements outside the protein-coding genes. There is a sea 
of non-coding transcripts [7,8], hundreds of thousands of 
genomic regions with potential regulatory function [9], 
and  hundreds  of  thousands  of  conserved  non-coding 
regions with unknown but presumably important func-
tion [10,11]. This substantial fraction of the genome, for 
which  we  do  not  know  the  functional  rules  and 
constraints, could harbor variants for which functional 
assays need to be developed. This is obviously a major 
obstacle in the evaluation of the majority of the genomic 
variability. It is expected that the technology used in the 
ENCODE  [9]  and  other  projects  will  enhance  our 
knowledge on the functional elements of our genomes. In 
addition,  it  is  well  known  that  the  contribution  of 
pathogenic variants to the phenotype is modified by the 
overall genomic variability of each individual, a notion in 
genetics known as ‘penetrance’. Thus, an experimentally 
proven  pathogenic  allele  may  result  in  a  phenotype  in 
some individuals, but not in others.
We now have the ability to read almost entire individual 
genomes in a reasonable time-frame, and this is cause for 
celebration. On the other hand, the daunting task in front 
of  us  is  the  functional  understanding  of  the  extensive 
genomic variation (common and rare) that now populates 
the hard disks of supercomputers and biobanks. The next 
decade  at  the  leading  edge  of  genetic  medicine  will 
certainly  be  dedicated  to  this  effort.  And  as  the  new 
graduate students and physicians in training now realize: 
sequencing is simple; functional understanding is still a 
dream.
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